Sustained delivery of dbcAMP by poly(propylene carbonate) micron fibers promotes axonal regenerative sprouting and functional recovery after spinal cord hemisection

Xia, Tongliang; Ni, Shilei; Li, Xingang; Yao, Jun; Qi, Hongxu; Fan, Xiaojing; Wang, Jiangang

doi:10.1016/j.brainres.2013.09.027

Cited by 22 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, dbcAMP, an analog of cAMP, was integrated into poly(propylene carbonate) fibers with the intent of reducing apoptosis, stimulating axonal growth, and decreasing astrogliosis in a spinal cord hemisection model (Xia et al, 2013). The scaffolds released dbcAMP over 8 days following an initial burst release during the first few hours.…”

Section: Biomaterials Therapeutics By Sci Pathophysiology Timelinementioning

confidence: 99%

“…Delivery of dbcAMP from fibers resulted in more axonal outgrowth and a lessening of glial scarring than without dbcAMP in vivo. Unfortunately, none of the axons were able to infiltrate the glial scar to reconnect, suggesting a simultaneous need for pharmacologics that reduce inhibitory factors post-injury (Xia et al, 2013). …”

Section: Biomaterials Therapeutics By Sci Pathophysiology Timelinementioning

confidence: 99%

See 1 more Smart Citation

Biomaterials for Local, Controlled Drug Delivery to the Injured Spinal Cord

Ziemba

Gilbert

2017

Front. Pharmacol.

View full text Add to dashboard Cite

Affecting approximately 17,000 new people each year, spinal cord injury (SCI) is a devastating injury that leads to permanent paraplegia or tetraplegia. Current pharmacological approaches are limited in their ability to ameliorate this injury pathophysiology, as many are not delivered locally, for a sustained duration, or at the correct injury time point. With this review, we aim to communicate the importance of combinatorial biomaterial and pharmacological approaches that target certain aspects of the dynamically changing pathophysiology of SCI. After reviewing the pathophysiology timeline, we present experimental biomaterial approaches to provide local sustained doses of drug. In this review, we present studies using a variety of biomaterials, including hydrogels, particles, and fibers/conduits for drug delivery. Subsequently, we discuss how each may be manipulated to optimize drug release during a specific time frame following SCI. Developing polymer biomaterials that can effectively release drug to target specific aspects of SCI pathophysiology will result in more efficacious approaches leading to better regeneration and recovery following SCI.

show abstract

Section: Biomaterials Therapeutics By Sci Pathophysiology Timelinementioning

confidence: 99%

Section: Biomaterials Therapeutics By Sci Pathophysiology Timelinementioning

confidence: 99%

Biomaterials for Local, Controlled Drug Delivery to the Injured Spinal Cord

Ziemba

Gilbert

2017

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Treated animals with low-dose rolipram experienced greater functional and anatomical recovery (Downing et al, 2012). Xia et al (2013) described the in vivo studies of poly (propylene carbonate) electrospun fibers as vehicle for the locally sustained delivery of dibutyryl cyclic adenosine monophosphate to promote the recovery of motor function after SCI (Xia et al, 2013). 2.…”

Section: Biocompatible Electrospun Scaffoldsmentioning

confidence: 99%

“…Treated animals with low‐dose rolipram experienced greater functional and anatomical recovery (Downing et al, ). Xia et al () described the in vivo studies of poly (propylene carbonate) electrospun fibers as vehicle for the locally sustained delivery of dibutyryl cyclic adenosine monophosphate to promote the recovery of motor function after SCI (Xia et al, ). Tailored core‐shell architectures have been fabricated by using co‐axial electrospinning to encapsulate the biological motifs (i.e., bio‐agents, drugs, or molecules) into the core material of fibrous matrices. In this way, functional motifs have no direct contact with cells after implantation even though they can be released locally in a controlled manner.…”

Section: Introductionmentioning

confidence: 99%

Recent therapeutic approaches for spinal cord injury

Raspa

Pugliese

Maleki

et al. 2015

Biotech & Bioengineering

View full text Add to dashboard Cite

A spinal cord injury (SCI) often causes permanent changes in strength and sensation functions below the site of the injury and affects thousands of people each year. Transplantation of stem cells is a promising approach in acute SCI as it may support spinal cord repair. However, in case of chronic SCI greater amounts of nervous tissue have to be regenerated, leaving scaffold transplantation the only feasible option for cellular engraftment and nervous bridging. The aim of regenerative medicine, specifically tissue engineering, is to create a microenvironment that mimics native extracellular matrix (ECM), capable of promoting specific cell-matrix interactions, coaxing cell behavior, and fostering host tissue regeneration. In this regard, nanostructured scaffolds are currently the most promising advanced substrates capable of supporting nervous fiber ingrowth and delivery of neurotrophic drugs. Among them, electrospinning technique and Self-Assembling Peptides (SAPs) have recently attracted lots of attention for their reproducible synthesis and high tailorability. This review highlights clinical trials and recent encouraging strategies for spinal cord repair comprising both cell therapy and nanomedicine.

show abstract

“…The intraperitoneal injection of VPA has some disadvantages. The injection method involves repeated punctures, in general twice a day for seven days (6,7,11), which can result in pain and infections (14). Therefore, biomaterial-based drug delivery systems such as microfibers present an additional platform to locally deliver VPA and therefore promote spinal cord tissue repair.…”

Section: Introductionmentioning

confidence: 99%

VPA/PLGA microfibers produced by coaxial electrospinning for the treatment of central nervous system injury

Reis

Sperling

Teixeira

et al. 2020

Braz J Med Biol Res

View full text Add to dashboard Cite

The central nervous system shows limited regenerative capacity after injury. Spinal cord injury (SCI) is a devastating traumatic injury resulting in loss of sensory, motor, and autonomic function distal from the level of injury. An appropriate combination of biomaterials and bioactive substances is currently thought to be a promising approach to treat this condition. Systemic administration of valproic acid (VPA) has been previously shown to promote functional recovery in animal models of SCI. In this study, VPA was encapsulated in poly(lactic-co-glycolic acid) (PLGA) microfibers by the coaxial electrospinning technique. Fibers showed continuous and cylindrical morphology, randomly oriented fibers, and compatible morphological and mechanical characteristics for application in SCI. Drug-release analysis indicated a rapid release of VPA during the first day of the in vitro test. The coaxial fibers containing VPA supported adhesion, viability, and proliferation of PC12 cells. In addition, the VPA/PLGA microfibers induced the reduction of PC12 cell viability, as has already been described in the literature. The biomaterials were implanted in rats after SCI. The groups that received the implants did not show increased functional recovery or tissue regeneration compared to the control. These results indicated the cytocompatibility of the VPA/PLGA core-shell microfibers and that it may be a promising approach to treat SCI when combined with other strategies.

show abstract

Sustained delivery of dbcAMP by poly(propylene carbonate) micron fibers promotes axonal regenerative sprouting and functional recovery after spinal cord hemisection

Cited by 22 publications

References 32 publications

Biomaterials for Local, Controlled Drug Delivery to the Injured Spinal Cord

Biomaterials for Local, Controlled Drug Delivery to the Injured Spinal Cord

Recent therapeutic approaches for spinal cord injury

VPA/PLGA microfibers produced by coaxial electrospinning for the treatment of central nervous system injury

Contact Info

Product

Resources

About